News
Drug Development
FDA
Manufacturing
Deals
Business
Job Trends
Cell and Gene Therapy
Cancer
Opinions
Press Releases
All News & Releases
Podcasts
Events
Jobs
Companies
Hotbeds
More
Reports
Career Advice
NextGen: Top Startups to Watch
40 Under 40
Best Places to Work
Employer Resources
Advertise
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
Submit an Event
SUBSCRIBE
Menu
SUBSCRIBE
Show Search
News
Drug Development
FDA
Manufacturing
Deals
Business
Job Trends
Cell and Gene Therapy
Cancer
Opinions
Press Releases
All News & Releases
Podcasts
Events
Jobs
Companies
Hotbeds
More
Reports
Career Advice
NextGen: Top Startups to Watch
40 Under 40
Best Places to Work
Employer Resources
Advertise
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
Submit an Event
Search Query
Submit Search
Search Results
Submit
Looking for jobs?
Search jobs
Close
175,725 Results
Type
Article (7803)
Company Profile (27)
Press Release (167894)
Multimedia
Podcasts (6)
Webinars (4)
Section
Business (49677)
Career Advice (378)
Deals (7415)
Drug Delivery (16)
Drug Development (27061)
Employer Resources (16)
FDA (4499)
Job Trends (3792)
News (86171)
Policy (5790)
Tag
2027 Biotech Bay Standard (1)
2027 Genetown Elite (1)
Academia (766)
Academic (1)
Accelerated approval (12)
Adcomms (2)
Allergies (63)
Alliances (10963)
ALS (81)
Alzheimer's disease (625)
Antibody-drug conjugate (ADC) (168)
Approvals (4810)
Artificial intelligence (260)
Autoimmune disease (80)
Automation (22)
Bankruptcy (31)
Best Places to Work (3651)
BIOSECURE Act (2)
Biosimilars (62)
Biotechnology (16)
Bladder cancer (120)
Brain cancer (29)
Breast cancer (401)
Cancer (2883)
Cardiovascular disease (187)
Career advice (314)
Career pathing (7)
CAR-T (114)
CDC (5)
Cell therapy (310)
Cervical cancer (24)
Clinical research (25082)
Collaboration (884)
Compensation (445)
Complete response letters (9)
COVID-19 (756)
CRISPR (44)
C-suite (376)
Cystic fibrosis (61)
Data (3844)
Denatured (1)
Depression (48)
Diabetes (217)
Diagnostics (3444)
Digital health (19)
Diversity (3)
Diversity, equity & inclusion (5)
Drug discovery (126)
Drug pricing (26)
Drug shortages (5)
Duchenne muscular dystrophy (91)
Earnings (29725)
Editorial (8)
Employer branding (3)
Employer resources (14)
Events (27101)
Executive appointments (484)
FDA (6098)
Fibrodysplasia Ossificans Progressiva (3)
Friedreich's ataxia (2)
Frontotemporal dementia (14)
Funding (703)
Gene editing (83)
Generative AI (15)
Gene therapy (229)
GLP-1 (301)
Government (886)
Grass and pollen (4)
Guidances (267)
Healthcare (4576)
HIV (30)
Huntington's disease (16)
IgA nephropathy (39)
Immunology and inflammation (81)
Immuno-oncology (23)
Indications (53)
Infectious disease (870)
Inflammatory bowel disease (86)
Inflation Reduction Act (3)
Influenza (61)
Intellectual property (77)
Interviews (61)
IPO (4332)
IRA (6)
Job creations (476)
Job search strategy (284)
JPM (11)
Kidney cancer (8)
Labor market (22)
Layoffs (100)
Leadership (4)
Legal (637)
Liver cancer (37)
Longevity (4)
Lung cancer (410)
Lymphoma (243)
Machine learning (19)
Management (4)
Manufacturing (252)
MASH (86)
Medical device (2468)
Medtech (2483)
Mergers & acquisitions (3598)
Metabolic disorders (490)
Multiple sclerosis (77)
NASH (4)
Neurodegenerative disease (140)
Neuropsychiatric disorders (34)
Neuroscience (1189)
NextGen: Class of 2026 (1123)
Non-profit (919)
Now hiring (13)
Obesity (178)
Opinion (43)
Ovarian cancer (82)
Pain (69)
Pancreatic cancer (114)
Parkinson's disease (139)
Partnered (8)
Patents (139)
Patient recruitment (215)
Peanut (25)
People (12230)
Pharmaceutical (7)
Pharmacy benefit managers (5)
Phase 1 (7418)
Phase 2 (10647)
Phase 3 (9189)
Pipeline (3100)
Policy (26)
Postmarket research (865)
Preclinical (3268)
Press Release (28)
Prostate cancer (142)
Psychedelics (8)
Radiopharmaceuticals (111)
Rare diseases (323)
Real estate (829)
Recruiting (5)
Regulatory (5983)
Reports (17)
Research institute (905)
Resumes & cover letters (64)
Rett syndrome (22)
RNA editing (3)
RSV (36)
Schizophrenia (76)
Series A (105)
Series B (89)
Sickle cell disease (38)
Special edition (3)
Spinal muscular atrophy (49)
Sponsored (8)
Startups (756)
Stomach cancer (3)
Supply chain (38)
Tariffs (14)
The Weekly (5)
Vaccines (285)
Venture capital (23)
Weight loss (85)
Women's health (23)
Worklife (2)
Date
Last 7 days (258)
Last 30 days (906)
Last 365 days (15104)
2026 (1282)
2025 (15451)
2024 (13432)
2023 (12856)
2022 (15833)
2021 (16203)
2020 (13911)
2019 (10690)
2018 (7803)
2017 (8405)
2016 (7533)
2015 (8826)
2014 (5905)
2013 (4505)
2012 (4770)
2011 (5125)
2010 (4291)
Location
Africa (142)
Alabama (25)
Alaska (2)
Arizona (58)
Arkansas (5)
Asia (10917)
Australia (1550)
California (5971)
Canada (1192)
China (558)
Colorado (183)
Connecticut (282)
Delaware (254)
Europe (26276)
Florida (540)
Georgia (118)
Hawaii (3)
Idaho (13)
Illinois (445)
India (22)
Indiana (192)
Iowa (13)
Japan (288)
Kansas (35)
Kentucky (12)
Louisiana (10)
Maine (14)
Maryland (569)
Massachusetts (4308)
Michigan (102)
Minnesota (245)
Mississippi (1)
Missouri (51)
Montana (7)
Nebraska (6)
Nevada (56)
New Hampshire (22)
New Jersey (1560)
New Mexico (14)
New York (1385)
North Carolina (549)
North Dakota (6)
Northern California (2983)
Ohio (149)
Oklahoma (5)
Oregon (15)
Pennsylvania (843)
Puerto Rico (4)
Rhode Island (16)
South America (200)
South Carolina (13)
Southern California (2218)
Tennessee (69)
Texas (903)
United States (19220)
Utah (183)
Vermont (1)
Virginia (136)
Washington D.C. (31)
Washington State (446)
West Virginia (2)
Wisconsin (94)
175,725 Results for "4d molecular therapeutics.rss".
Filters
Sort By
Relevance
Relevance
Newest
Oldest
Press Releases
Microbix Presents Molecular Pathology Platform Results
February 4, 2026
·
5 min read
Press Releases
Biodexa Announces Exclusive License of Otsuka’s OPB-171775, a potent Phase 1 ready Molecular Glue for GIST
February 5, 2026
·
7 min read
Press Releases
Bayer to Expand Into Molecular Imaging With Acquisition of Innovative Pan-Amyloid Radiotracers From Attralus
January 12, 2026
·
9 min read
Collaboration
Novartis Sticks With Monte Rosa in Second Molecular Glue Deal Worth up to $5.7B
Novartis and Monte Rosa first partnered in October 2024 for a molecular glue asset for immune-mediated and autoimmune diseases. This time, the pharma is putting $120 million down upfront for more of the biotech’s AI-discovered degraders.
September 15, 2025
·
2 min read
·
Tristan Manalac
Press Releases
Synthego Announces Entry into Molecular Biology and Clinical Diagnostic Reagents Market
January 13, 2026
·
3 min read
Press Releases
4DMT Announces Positive Interim Clinical Data from 4D-710 AEROW Phase 1 Clinical Trial in Cystic Fibrosis Lung Disease
December 17, 2025
·
9 min read
Press Releases
4D Path Joins Phase II Clinical Trial to Advance Predictive Biomarkers in Bladder Cancer
January 23, 2026
·
4 min read
Press Releases
4DMT Advances 4D-710 to Phase 2 with Additional Funding and Support from the Cystic Fibrosis Foundation
October 14, 2025
·
9 min read
Press Releases
4DMT Announces Exclusive License Agreement with Otsuka Pharmaceutical Co., Ltd. for Development and Commercialization of 4D-150 in Asia-Pacific
October 31, 2025
·
8 min read
Press Releases
Study Establishes Molecular Link Between Tumor Metabolism and Drug Engagement in Cancer Cells
December 10, 2025
·
8 min read
1 of 17,573
Next
